Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | P4HTM | Q9NXG6 | 17/20 | 0.66 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.66 |
| ▸ | MIF | P14174 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6553707 | 0.98 | MAPK1 (0.96) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL29508473 | 0.89 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL69747 | 0.89 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL14332845 | 0.86 | KDM4E (0.75) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL10284462 | 0.86 | MAPK1 (0.75) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL423045 | 0.85 | MAPK1 (0.79) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL29826109 | 0.85 | MAPK1 (0.79) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL64024 | 0.85 | MAPK1 (0.79) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL5717551 | 0.84 | MAPK1 (0.77) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 | |
| SCHEMBL378814 | 0.84 | MAPK1 (0.77) | MAPK1KDM4EL3MBTL1P4HTMP4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117506232-A | Resin tin paste with residual after adhesive welding and preparation method thereof | 深圳市鸿慷电子有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-113234013-B | Compound for inhibiting collagen synthesis and deposition and application thereof | 杭州医学院 | 2022-05-24 | — | — | CN | claimed |
| CN-113234013-A | Compound for inhibiting collagen synthesis and deposition and application thereof | 杭州医学院 | 2021-08-10 | — | — | CN | claimed |
| US-6306860-B1 | ANTIVIRAL ACTIVITIES AGAINST HEPATATIS B AS WELL AS HUMAN IMMUNODEFICIENCY VIRUS | DONG WHA PHARM. INC. CO., LTD. (KR) | 2001-10-23 | — | — | US | claimed |
| CN-1305472-A | Novel 2,5-pyridinedicarboxylic acid derivatives | DONY WHA PARM IND CO LTD (KR) | 2001-07-25 | — | — | CN | claimed |
| WO-1999058526-A1 | NOVEL 2,5-PYRIDINEDICARBOXYLIC ACID DERIVATIVES | DONG WHA PHARM. IND. CO., LTD. (KR) | 1999-11-18 | — | — | WO | claimed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688777-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2026-02-11 | — | — | EP | disclosed |
| US-20260014174-A1 | DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR | PURDUE RESEARCH FOUNDATION (US) | 2026-01-15 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3774767-B1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| CN-1107144-A | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1995-08-23 | — | — | CN | disclosed |
| US-5420145-A | Antileukemia | Shudo, Koichi (JP) | 1995-05-30 | — | — | US | disclosed |
| US-5364873-A | Influencing metabolism of collagen | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| EP-0617020-A1 | Carboxylic acid derivatives having retinoic acid-like activity | Shudo, Koichi, Prof. Dr. (JP) | 1994-09-28 | — | — | EP | disclosed |
| US-5238948-A | Influence metabolism of collagen or biosynthesis of C1q | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-24 | — | — | US | disclosed |
| CN-1060464-A | 4-or 5-substituted pyridines-2-carboxylic acid, their preparation method and medicinal | HOECHST AG (DE) | 1992-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014174-A1 | DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR | HDAC3, HDAC1, HDAC11 | MAPK1 769/4885KDM4E 194/4885L3MBTL1 592/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | MAPK1 1183/4885KDM4E 1970/4885L3MBTL1 1047/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | MAPK1 3302/4885KDM4E 4270/4885L3MBTL1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.